What's new? Log in Free sign up

Avid Bioservices (CDMO)

Company Profile

Company profile

Ticker

CDMO

Exchange

Website

www.avidbio.com

CEO

Mr. Nicholas Stewart Green B.Sc., MBA

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

PEREGRINE PHARMACEUTICALS INC, TECHNICLONE CORP/DE/, TECHNICLONE INTERNATIONAL CORP

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

953698422

CDMO stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Securities registration termination

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Registration of securities for employees (post-effective amendment)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Point72 Asset Management, L.P.

Richard A. Richieri

CATHERINE J MACKEY

Matthew R. Kwietniak

Richard B Hancock

Nicholas Stewart Green

Financial summary

Financial statements Chart CDMO financial data

Quarter (USD)	Oct 24	Jul 24	Apr 24	Jan 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Apr 24	Apr 23	Apr 22	Apr 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	33.42 mm	33.42 mm	33.42 mm	33.42 mm	33.42 mm	33.42 mm
Cash burn (monthly)	(no burn)	(no burn)	5.80 mm	2.94 mm	(no burn)	(no burn)
Cash used (since last report)	n/a	n/a	23.62 mm	11.95 mm	n/a	n/a
Cash remaining	n/a	n/a	9.79 mm	21.46 mm	n/a	n/a
Runway (months of cash)	n/a	n/a	1.7	7.3	n/a	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

CDMO institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	199	176	+13.1%
Opened positions	66	27	+144.4%
Closed positions	43	26	+65.4%
Increased positions	45	58	-22.4%
Reduced positions	53	48	+10.4%

13F shares	Current	Prev Q	Change
Total value	751.42 bn	722.14 bn	+4.1%
Total shares	72.92 mm	77.09 mm	-5.4%
Total puts	4.60 k	118.30 k	-96.1%
Total calls	215.50 k	89.90 k	+139.7%
Total put/call ratio	0.0	1.3	-98.4%

Largest owners	Shares	Value	Change
BlackRock	5.26 mm	$64.99 bn	+0.1%
AltraVue Capital	3.80 mm	$46.90 bn	0.0%
Vanguard	3.77 mm	$46.57 bn	-2.0%
Glazer Capital	3.72 mm	$45.91 mm	NEW
Punch & Associates Investment Management	2.88 mm	$35.62 bn	-1.7%
STT State Street	2.67 mm	$33.02 bn	-11.0%
FIL	2.56 mm	$31.60 bn	NEW
RY Royal Bank of Canada	2.51 mm	$30.96 bn	-11.4%
Iszo Capital	2.38 mm	$27.43 mm	0.0%
Tappan Street Partners	2.18 mm	$64.66 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Point72 Asset Management	0.00	-3.82 mm	EXIT
Millennium Management	375.05 k	-3.81 mm	-91.0%
Glazer Capital	3.72 mm	+3.72 mm	NEW
Integrated Core Strategies	880.97 k	-3.36 mm	-79.2%
First Light Asset Management	0.00	-2.77 mm	EXIT
FIL	2.56 mm	+2.56 mm	NEW
Palisade Capital Management	0.00	-1.96 mm	EXIT
Alpine Associates Management	1.95 mm	+1.95 mm	NEW
Highland Capital Management Fund Advisors	1.85 mm	+1.85 mm	NEW
Portolan Capital Management	455.04 k	-1.64 mm	-78.3%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CDMO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 Feb 25	Esther M. Alegria	Common Stock, $0.001 par value	Sale back to company	Dispose D	No	No	0	37,746	0.00	0
5 Feb 25	Esther M. Alegria	RSU Common Stock	Sale back to company	Dispose D	No	No	0	8,147	0.00	0
5 Feb 25	Esther M. Alegria	Stock Option Common Stock	Sale back to company	Dispose D	No	No	26.03	8,376	218.03 k	0
5 Feb 25	Hart Daniel Ryan	Common Stock, $0.001 par value	Sale back to company	Dispose D	No	No	0	112,735	0.00	0
5 Feb 25	Hart Daniel Ryan	Performance Stock Units Common Stock	Sale back to company	Dispose D	No	No	0	113,878	0.00	0
5 Feb 25	Hart Daniel Ryan	Performance Stock Units Common Stock	Sale back to company	Dispose D	No	No	0	2,938	0.00	113,878
5 Feb 25	Hart Daniel Ryan	RSU Common Stock	Sale back to company	Dispose D	No	No	0	92,461	0.00	0
5 Feb 25	Hart Daniel Ryan	RSU Common Stock	Sale back to company	Dispose D	No	No	0	30,635	0.00	92,461
5 Feb 25	Hart Daniel Ryan	Stock Option Common Stock	Sale back to company	Dispose D	No	No	6.95	71,120	494.28 k	0
5 Feb 25	Hart Daniel Ryan	Stock Option Common Stock	Sale back to company	Dispose D	No	No	6.07	54,760	332.39 k	71,120

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Avid Bioservices Q2 EPS $(0.27) Misses $(0.12) Estimate, Sales $33.50M Miss $33.80M Estimate

Avid Bioservices (NASDAQ:CDMO) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.12) by 125 percent. This is a 80 percent decrease over losses of $(0.15) per share from the

Press releases

From Benzinga Pro

Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience

TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing

Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger

TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve patient lives by

Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners

Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completedGHO and Ampersand's deep experience in CDMO investing to support Avid's next stage of rapid growth including

Avid Reminds Stockholders to Vote Today FOR the Transaction with GHO and Ampersand

Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.